Christopher H Gibbons1, Jennifer Garcia2, Ningshan Wang2, Ludy C Shih2, Roy Freeman2. 1. From the Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. cgibbons@bidmc.harvard.edu. 2. From the Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: To determine the diagnostic discrimination of cutaneous α-synuclein deposition in individuals with Parkinson disease (PD) with and without autonomic dysfunction on autonomic testing, in early and late stages of the disease, and of short and long duration. METHODS: Twenty-eight participants with PD and 23 control participants were studied by skin biopsies at multiple sites, autonomic function testing, and disease-specific scales. RESULTS: Skin biopsies provide >90% sensitivity and >90% specificity to distinguish PD from control participants across all biopsies sites with quantification of either pilomotor or sudomotor α-synuclein deposition. All individuals with PD have significantly higher cutaneous α-synuclein deposition than control participants, even those individuals with PD and no evidence of autonomic dysfunction. Deposition of α-synuclein is most prominent in sympathetic adrenergic nerve fibers innervating the arrector pili muscles, but is also present in sudomotor (sympathetic cholinergic) nerve fibers. α-Synuclein is present even in the early stages of disease and disease of short duration. α-Synuclein ratios were higher in individuals with autonomic failure, with more advanced stages of disease and disease of longer duration. CONCLUSIONS: The α-synuclein ratio provides a sensitive and specific diagnostic biomarker of PD even in patients without autonomic failure. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that cutaneous α-synuclein deposition accurately identifies patients with PD.
OBJECTIVE: To determine the diagnostic discrimination of cutaneous α-synuclein deposition in individuals with Parkinson disease (PD) with and without autonomic dysfunction on autonomic testing, in early and late stages of the disease, and of short and long duration. METHODS: Twenty-eight participants with PD and 23 control participants were studied by skin biopsies at multiple sites, autonomic function testing, and disease-specific scales. RESULTS: Skin biopsies provide >90% sensitivity and >90% specificity to distinguish PD from control participants across all biopsies sites with quantification of either pilomotor or sudomotor α-synuclein deposition. All individuals with PD have significantly higher cutaneous α-synuclein deposition than control participants, even those individuals with PD and no evidence of autonomic dysfunction. Deposition of α-synuclein is most prominent in sympathetic adrenergic nerve fibers innervating the arrector pili muscles, but is also present in sudomotor (sympathetic cholinergic) nerve fibers. α-Synuclein is present even in the early stages of disease and disease of short duration. α-Synuclein ratios were higher in individuals with autonomic failure, with more advanced stages of disease and disease of longer duration. CONCLUSIONS: The α-synuclein ratio provides a sensitive and specific diagnostic biomarker of PD even in patients without autonomic failure. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that cutaneous α-synuclein deposition accurately identifies patients with PD.
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: G Lauria; S T Hsieh; O Johansson; W R Kennedy; J M Leger; S I Mellgren; M Nolano; I S J Merkies; M Polydefkis; A G Smith; C Sommer; J Valls-Solé Journal: Eur J Neurol Date: 2010-07 Impact factor: 6.089
Authors: David S Goldstein; Yehonatan Sharabi; Barbara I Karp; Oladi Bentho; Ahmed Saleem; Karel Pacak; Graeme Eisenhofer Journal: Cleve Clin J Med Date: 2009-04 Impact factor: 2.321
Authors: Maria Nolano; Vincenzo Provitera; Anna Estraneo; Mona M Selim; Giuseppe Caporaso; Annamaria Stancanelli; Anna Maria Saltalamacchia; Bernardo Lanzillo; Lucio Santoro Journal: Brain Date: 2008-05-31 Impact factor: 13.501
Authors: Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma; Italo Biaggioni; Phillip A Low; Wolfgang Singer; David S Goldstein; Amanda C Peltier; Cyndia A Shibao; Christopher H Gibbons; Roy Freeman; David Robertson Journal: Ann Neurol Date: 2017-02 Impact factor: 10.422
Authors: Risa Isonaka; Avi Z Rosenberg; Patti Sullivan; Abraham Corrales; Courtney Holmes; Yehonatan Sharabi; David S Goldstein Journal: Hypertension Date: 2019-04 Impact factor: 10.190
Authors: Risa Isonaka; Christopher H Gibbons; Ningshan Wang; Roy Freeman; David S Goldstein Journal: Clin Auton Res Date: 2019-10-31 Impact factor: 4.435
Authors: Thomas G Beach; Geidy E Serrano; Thomas Kremer; Marta Canamero; Sebastian Dziadek; Hadassah Sade; Pascal Derkinderen; Anne-Gaëlle Corbillé; Franck Letournel; David G Munoz; Charles L White; Julie Schneider; John F Crary; Lucia I Sue; Charles H Adler; Michael J Glass; Anthony J Intorcia; Jessica E Walker; Tatiana Foroud; Christopher S Coffey; Dixie Ecklund; Holly Riss; Jennifer Goßmann; Fatima König; Catherine M Kopil; Vanessa Arnedo; Lindsey Riley; Carly Linder; Kuldip D Dave; Danna Jennings; John Seibyl; Brit Mollenhauer; Lana Chahine Journal: J Neuropathol Exp Neurol Date: 2018-09-01 Impact factor: 3.685